About Careers Internship MedBlog Contact us

'Encouraging' Results of Ebola Drug Trial in Guinea

by Himabindu Venkatakrishnan on February 5, 2015 at 9:53 PM
Font : A-A+

'Encouraging' Results of Ebola Drug Trial in Guinea

"Encouraging" results were seen in an Ebola candidate during a trial among a sample of 80 patients in Guinea, where the medics observed faster recovery rates, the French government and medical research agency Inserm said today.

No scientific trial data has been made public, but the preliminary results are the first to show efficacy of an experimental treatment for the Ebola virus which has infected 22,495 people and killed 8,981 in the worst outbreak in history, according to the latest tally by the World Health Organization.


"Encouraging results of the trial" with Japanese-manufactured anti-viral drug favipiravir "will be submitted shortly to a scientific journal for publication", an Inserm statement to AFP said.

The French government said in a separate statement that faster recovery rates were reported among the 80 infected adults and children who received the drug.

The results "show a reduction in the number of deaths among adults and teenagers, with slower virus multiplication. Recovery is accelerated," said the Elysee palace.

The head of France's Ebola Task Force, Jean-Francois Delfraissy, and Inserm head Yves Levy briefed President Francois Hollande and government officials on Wednesday, it added, and described the results as "an important step forward".

Inserm is in charge of the trial at a treatment centre in Gueckedou in the east of Guinea one of the three countries, with Liberia and Sierra Leone, hardest hit by the outbreak.

The trial, which started on December 17, was conducted in partnership with Guinean researchers and authorities, non-government organisations, the French Red Cross and aid group Doctors Without Borders (MSF).

It is the largest clinical trial yet with a candidate Ebola treatment, the French statement said.

Favipiravir, also known as Avigan, is developed by Toyama Chemical, a subsidiary of Fujifilm Holdings.

Inserm said the scientific results will be made public once they have been officially reviewed and validated by the scientific community, which could happen by month's end.

The drug has already been administered as an emergency treatment to patients evacuated from West Africa to Europe, though this was not part of an official trial.

It has commercial authorisation in Japan as a flu medicine, and large doses can be made quickly available an advantage over other experimental treatments, like ZMapp, of which stocks are limited.

The Elysee said the results gave rise to "hope", but cautioned they have to be confirmed with a larger group of trial patients.

"These early results open new avenues for access to treatment in the fight against this disease," it said adding the outcome will be discussed Thursday at a meeting between Guinean President Alpha Conde, Delfraissy and Levy.

There is as yet no licensed vaccine or treatment for Ebola. The WHO gave the green light last August for experimental treatment to be used in the current crisis, and several experimental drugs are being fast-tracked through the normally years-long trial process.


Recommended Readings

Latest Tropical Disease News

Oral Cholera Vaccine Launched in India by Pharma Giants
Mumbai's TechInvention Lifecare and South Korean Eubiologics team up to introduce oral cholera vaccine in India after successful phase III clinical trial.
Evolving Threat of Dengue Virus in India
Scientists have found that the dengue virus has become more severe in India, highlighting the urgent need for vaccines that target the strains found in the country.
 Watch Out for Acute Kidney Disease as a Complication of Malaria
It is important to consider malarial infection in cases of acute kidney injury in someone with a travel history from endemic areas to improve treatment outcomes.
India's Malaria Vaccine Gets the Green Light for First Time in Ghana
Ghana approves the use of the University of Oxford's malaria vaccine, produced by the Serum Institute of India (SII), becoming the first country to adopt the new vaccine.
 Deadly Dengue Virus Hijacks Mosquito Saliva to Spread Sickness
The dengue virus combines molecules from its RNA with mosquito saliva to foil the human immune system and spread dengue fever and related diseases.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

'Encouraging' Results of Ebola Drug Trial in Guinea Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests